Explore the latest in pharmacoeconomics, including cost-effectiveness evaluations, value-based pricing, coverage and access, and more.
This study uses wholesale medication acquisition costs and Medicare claims data to assess how prices of existing tumor necrosis factor inhibitors changed in response to the market entry of new tumor necrosis factor inhibitors.
This Viewpoint reviews unintended consequences of the 1983 Orphan Drug Act, which incentivized development of drugs for rare diseases, including abbreviated approval processes for manufacturers and surges in drug costs, and calls for revision of the “orphan drug” definition in an era where precision medicine will narrow patient populations sufficiently to make any drug qualify for an “orphan” designation.
This study uses Medicare Part D prescription drug plan formulary files to characterize changes in coverage of buprenorphine and buprenorphine-naloxone for opioid use disorder in 2007, 2012, and 2018.
This Viewpoint discusses the bias experts can introduce to pharmacy and therapeutics committees tasked with evaluating the value of adding new drugs to practice formularies and proposes strategies to reduce bias including anonymous voting; allowing members time for thoughtful review; and training members in study design, critical appraisal, and cost-benefit analysis.
This Markov model study assesses the cost-effectiveness of capecitabine and bevacizumab maintenance therapy after induction chemotherapy for treatment of metastatic colorectal cancer.
This Viewpoint uses results of randomized clinical trials to explore whether the use of abiraterone acetate plus prednisone is a cost-effective and appropriate treatment option for patients with nonmetastatic castration-resistant prostate cancer.
This cost-effectiveness analysis estimates the lifetime costs and quality-adjusted life-years associated with adding canakinumab to standard of care for the secondary prevention of major cardiovascular events.
This cohort study examined associations of an intervention to encourage Medicare beneficiaries with type 2 diabetes to switch from analogue to human insulin with hemoglobin A1c1c (HBA1c) levels, serious hypoglycemic and serious hyperglycemic events, and total spending on insulin products.
This survey-based behavioral experiment was conducted to understand how consumers are likely to respond to including the drug price in any direct-to-consumer pharmaceutical advertising.
This analysis of Medicaid reimbursement data examines the financial implications of removing the Medicaid rebate cap.
This study uses the most recent national data available from Medicare and the Department of Veterans Affairs to quantify the savings Medicare Part D would achieve if it paid the same prices for prescription drugs currently paid by the Department of Veterans Affairs.
This analysis of 75 brand-name drugs uses Medicare data to estimate the costs of proposed Medicare Part B and Part D reforms on total drug spending and patient cost-sharing for prescription drugs.
This study assesses and compares changes in the prices of adalimumab, ranibizumab, and aflibercept in the United States and Australia.
This observational study determines whether sale incomes and research and development (R&D) costs for US Food and Drug Administration (FDA)–approved cancer drugs sold by originator drug companies justify high prices for cancer drugs.
This economic evaluation assesses the cost-effectiveness of talimogene laherparepvec plus ipilimumab combination therapy vs ipilimumab monotherapy in patients with advanced unresectable melanoma from the perspective of public and private US payers.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: